CN103285284A - Medical composition for treating senile vaginitis - Google Patents
Medical composition for treating senile vaginitis Download PDFInfo
- Publication number
- CN103285284A CN103285284A CN2013102675007A CN201310267500A CN103285284A CN 103285284 A CN103285284 A CN 103285284A CN 2013102675007 A CN2013102675007 A CN 2013102675007A CN 201310267500 A CN201310267500 A CN 201310267500A CN 103285284 A CN103285284 A CN 103285284A
- Authority
- CN
- China
- Prior art keywords
- parts
- brown
- parched
- senile vaginitis
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 title claims abstract description 18
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 5
- 241001604597 Pyrestini Species 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims description 36
- 241000628997 Flos Species 0.000 claims description 12
- 239000010271 massa medicata fermentata Substances 0.000 claims description 12
- 241000218671 Ephedra Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 7
- 244000144730 Amygdalus persica Species 0.000 abstract description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 2
- 241001193853 Dalbergia mimosoides Species 0.000 abstract description 2
- 241000007357 Magnolia amoena Species 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 241000913828 Apios Species 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 244000290970 Tetrapanax papyrifer Species 0.000 abstract 1
- 241000765991 Trikeraia hookeri Species 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000004939 coking Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 18
- 210000004877 mucosa Anatomy 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000167696 Prenanthes Species 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 241000068277 Apios fortunei Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000723237 Ephedra intermedia Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 241000218670 Ephedraceae Species 0.000 description 1
- 244000070010 Erythrina variegata Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001362856 Lepisorus miyoshianus Species 0.000 description 1
- 241000221040 Loranthaceae Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 241000316341 Taxillus chinensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000006067 antibiotic powder Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000006669 vulvar dystrophy Diseases 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medical composition for treating senile vaginitis and a preparation method thereof, and aims at solving the treatment problem of the senile vaginitis. The medicinal composition is characterized by being prepared from the following active pharmaceutical ingredients: cortex erythrinae, trikeraia hookeri, tetrapanaxpapyrifer, Magnolia amoena, ramulus loranthi, apios fortune maxim, coking malt, stir-baked massa fermentata medicinalis, radices ephedrae, dalbergia mimosoides franch leaf, peach gum and cassia twig. Clinical experiments prove that the medical composition disclosed by the invention has the characteristics of good curative effect and quite high safety when being used for treating the senile vaginitis, thereby being worthy of clinical application and promotion.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of senile vaginitis.
Background technology
Senile vaginitis is common in postclimacteric elderly woman, and because of the ovarian function decline, estrogen level reduces, the vaginal wall atrophy, the mucosa attenuation, glycogen content reduces in the epithelial cell, intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are invaded breeding easily and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.Inspection sees that vagina is senile change, last atrophoderma, and pleat disappears, and it is sliding, poor that epithelium flattens.Vaginal mucosa hyperemia has little petechia, sees shallow table ulcer sometimes.
Senile vaginitis Therapeutic Principle is for increasing the growth and breeding of vagina resistance and inhibition antibacterial.Present western medical treatment mostly is and replenishes a small amount of estrogen, and vaginal mucosa is thickened, and builds up resistance.But estrogenic unreasonable use easily causes carcinoma of endometrium and breast carcinoma, so there is dispute in this kind therapeutic scheme always.Bacteria growing inhibiting is then for to put into the antibiotic powder in intravaginal, but life-time service can cause local dysbacteriosis, causes bigger puzzlement.
And the colpitic suppository of Chinese traditional treatment, outer lotion are many, but be mostly at the child-bearing period women, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of senile vaginitis causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes the state of an illness to increase the weight of.
Summary of the invention
Technical assignment of the present invention is at above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the treatment senile vaginitis that side effect is little.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of senile vaginitis is characterized in that being prepared from by following materials of weight proportions medicine: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Chlorophyti Laxis, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Flos Magnoliae Amoenae, 6 ~ 12 parts of 3 ~ 10 parts of, Radix Apioris Fortunei of Herba Taxilli, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Folium Dalbergiae Mimosoidis, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Ramulus Cinnamomi.
Chinese medicine of the present invention is prepared from by following optimum weight part proportion raw material: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..The nature and flavor hardship, flat.Return liver, kidney channel.But the merit wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.But merit heat-clearing and toxic substances removing; The dissipating blood stasis hemostasis.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.But merit tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; The wind syndrome of head headache; The weak breath consumption of essence; Early whitening of beard and hair.
Flos Magnoliae Amoenae for Magnoliaceae head Drymotaenium miyoshianum (Mak.) Mak. Magnolia amoena Cheng, is used as medicine with alabastrum.The nature and flavor hardship, cold.But the merit diuresis, detumescence, nourishing the lung to arrest cough.
Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser for Herba Taxilli.Nature and flavor hardship, sweet, flat.Return liver, kidney channel.But the merit invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Apioris Fortunei for pulse family Radix Apioris Fortunei platymiscium Radix Apioris Fortunei Apios fortunei Maxim., is used as medicine with tuber, leaf and seed.Sweet, the little hardship of nature and flavor, flat.But the merit heat-clearing and toxic substances removing, preventing phlegm from forming and stopping coughing.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. through the drying of germinateing, fry to burnt brown according to the method for frying, cool sieve dedust bits.Nature and flavor are sweet, and are flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven that fermentation forms, fry to burnt brown according to frying method.The sweet suffering of nature and flavor, temperature.Go into spleen, stomach warp.But the merit invigorating the spleen and regulating the stomach is in the accent that helps digestion.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, and are flat.GUIXIN, lung meridian.But merit hidroschesis.
Folium Dalbergiae Mimosoidis is the leaf of leguminous plant trunk rattan Dalbergia mimosoides Franch.GUIXIN; Spleen channel.But merit heat-clearing and toxic substances removing.
Gumshiraz is rosaceous plant peach Prunus persica (L.) Batsch, the resin that flows out on the trunk.Nature and flavor hardship, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Ramulus Cinnamomi is the dry twig of canella Cortex Cinnamomi Cinnamomum cassia Presl.Nature and flavor suffering, sweet, temperature.GUIXIN, lung, urinary bladder channel.But merit diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.
Composition principle: senile vaginitis is common in postclimacteric elderly woman, because of the ovarian function decline, the a lot of levels of estrogen reduce, the vaginal wall atrophy, glycogen content reduces in the mucosa attenuation, epithelial cell, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are invaded breeding easily and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.At present the colpitic suppository of Chinese traditional treatment, outer lotion are many, but be mostly at the child-bearing period women, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of senile vaginitis causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes the state of an illness to increase the weight of.The objective of the invention is to avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, the vaginal wall atrophy, this pathological change angle of mucosa attenuation is started with, and reaches the purpose of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription uniqueness, avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in the side, go back bobbin and be monarch, Cortex erythrinae dosage of record is in " China's book on Chinese herbal medicine ": " taking orally: fry in shallow oil soup, 6-12g "; (10 ~ 30g) can recover by specific promotion vaginal wall mucosa heavy dose of Cortex erythrinae during the inventor experimental results show that, and go back bobbin the similar plants estrogen action is arranged, but this act as two-ways regulation, can not produce the low differentiation of the excessive stimulation reproductive system of estrogen cell;
2, characteristic of the present invention also is balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbidding ", but the gerontal patient is often with the resembling of deficiency of YIN-blood, and use Cortex erythrinae this moment then has its hematozemia of fearing and causes the interior-heat caused by deficiency of YIN appearance; So add Herba Chlorophyti Laxi and go back bobbin, also but the training of bobbin merit tonify deficiency is basic, and can prevent that Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and the Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize its cold heated that prevents on the one hand, but its merit dissipating blood stasis hemostasis on the other hand there is out entire merit in blood system, prevent the Cortex erythrinae moving blood of wandering away, also can not influence Cortex erythrinae simultaneously and work orderly effect; 2. the use of Ramulus Cinnamomi is among the we: a promoting the flow of QI-blood by warming the meridian, and supporing yang activating QI, two Yin Yang balancings are with the bitter cold of balance we invasion by pathogenic cold medicine of a cold nature thing; The application characteristic of Ramulus Cinnamomi is in the prescription of the present invention: measure that bigger (" consumption in the Chinese pharmacopoeia is 3 ~ 9g), so too disperse for preventing, gets Radix Ephedrae convergence assistant system again;
3, the supplementary drug thing is fewer but better: get the Flos Magnoliae Amoenae assistant in the side and help Herba Chlorophyti Laxi, heat conduction is descending; The Radix Apioris Fortunei heat-clearing and toxic substances removing; The Herba Taxilli assistant helps goes back the bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and helps medicine to stay in mucomembranous surface, promotes to absorb;
4, inventor's clinical research finds that Fructus Hordei Germinatus (parched to brown), the external of Massa Medicata Fermentata (parched to brown) decoct can promote the local mucous membrane blood circulation;
5, Folium Dalbergiae Mimosoidis is the supplementary drug thing, in " China book on Chinese herbal medicine " record consumption be: " for oral administration: as to fry in shallow oil soup, 9 ~ 15g ", inventor's experimental study are found, get low dose of Folium Dalbergiae Mimosoidis decocting liquid and can improve the vaginal mucosa cytoactive that exsomatizes;
6, the thing homogeneous medicine multiple-effect of getting it filled in the side helps to reduce medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have curative effect preferably in the following weight parts scope.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Flos Magnoliae Amoenae 10g, Herba Taxilli 6g, Radix Apioris Fortunei 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Folium Dalbergiae Mimosoidis 2g, gumshiraz 6g, Ramulus Cinnamomi 20g.
The preparation method of embodiment 1 is: with Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Flos Magnoliae Amoenae, Herba Taxilli, Radix Apioris Fortunei, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Folium Dalbergiae Mimosoidis, gumshiraz, Ramulus Cinnamomi mixing and water adding and decoct, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, the crude drug weight proportion: 10 parts of Cortex erythrinaes, 6 parts of Herba Chlorophyti Laxis, go back 3 parts in bobbin, 6 parts of Flos Magnoliae Amoenae, 6 parts of 3 parts of, Radix Apioris Fortunei of Herba Taxilli, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 6 parts of Massa Medicata Fermentata (parched to brown), 6 parts of Radix Ephedraes, 1 part of Folium Dalbergiae Mimosoidis, 3 parts of gumshiraz, 10 parts of Ramulus Cinnamomi.
Embodiment 3, the crude drug weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Embodiment 4, the crude drug weight proportion: 30 parts of Cortex erythrinaes, 12 parts of Herba Chlorophyti Laxis, go back 10 parts in bobbin, 12 parts of Flos Magnoliae Amoenae, 12 parts of 10 parts of, Radix Apioris Fortunei of Herba Taxilli, 12 parts of Fructus Hordei Germinatus (parched to brown)s, 12 parts of Massa Medicata Fermentata (parched to brown), 12 parts of Radix Ephedraes, 5 parts of Folium Dalbergiae Mimosoidiss, 10 parts of gumshiraz, 25 parts of Ramulus Cinnamomi.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Apioris Fortunei, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and collect back mixing for standby use, medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill after-filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Dalbergiae Mimosoidis, gumshiraz, Ramulus Cinnamomi and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill after-filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, and drying and crushing gets dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose for the treatment of senile vaginitis, and side effect is less.The above results is that clinical data proves that fully interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case is selected: in March, 2011 ~ 2013 are diagnosed as senile vaginitis 248 examples year April, 49 years old～69 years old age, be menopausal women, and be limited to 1 year menopause ~ 20 years.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all case is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is xerosis vulae, the pale or flushing of vaginal mucosa or little petechia is arranged, vaginal health scoring＜15 minutes, serum follicle stimulating hormone (FSH) 〉=40IU/L, serum estradiol (E2)≤110pmol/L, abdominal ultrasound examination endometrium thickness＜5mm.All patients all carry out the vaginal secretions inspection and get rid of trichomonal vaginitis, monilial vaginitis before treatment, urine is cultivated negative, no vulvar dystrophy and dermatosis.All cases are got rid of hormone-dependent tumor, do not accept the hormone medicine treatment over nearly 3 months.
1.1.3 grouping: be divided into washout group and powder group, every group of 124 examples.Compare in age, the state of an illness, the course of disease before two groups of patient treatments, and the difference not statistically significant (P〉0.05), have comparability.
1.2 method.
1.2.1 Therapeutic Method: the washout group is with gained decoct washout in the embodiment of the invention 1,1 time/d.The powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the invention 3,1 time/d.14 days is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after the medication, and according to vaginal health point system (VHS) scoring, determine the doing well,improving situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Produce effects: clinical symptoms, sign turn for the better by and large; Effectively: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign no change.
1.2.4 statistical analysis: SPSS 13.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data is checked with t, enumeration data χ
2Check.
2 results.
2.1 vaginal symptoms is improved situation: all case vagina drying, dyspareunia symptom all begin to obtain improvement in various degree behind the medication 5d.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and the surface is pale, flushing and bleeding are clearly better.According to the vaginal health standards of grading, the vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, 5 project score values of secretions.Scoring is 8.52 ± 1.32 before the washout group patient medication, and the scoring average is 13.23 ± 1.63 behind the medication 14d.Scoring is 9.14 ± 2.02 before the powder group patient medication, and the scoring average is 17.72 ± 2.62 behind the medication 14d.Relatively, (P＜0.05) is all obviously increased in the vaginal health scoring behind two groups of patient treatments before and after the medication.
2.2 two groups of clinical comprehensive therapeutic effects relatively: the cure rate of washout group, obvious effective rate, effective percentage, inefficiency are respectively 57.26%, 33.87%, 8.87%, 0%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 71.77%, 16.94%, 11.29%, 0%.Two groups relatively, and the cure rate of powder group is apparently higher than washout group (χ
2=4.77, P＜0.05).
2.3 adverse reaction rate: obvious adverse reaction does not all appear in two groups of patients.
2.4 relapse rate: in 3 months, the washout group has 3.23%(4/124) case appearance recurrence, the powder group has 0.81%(1/124) case appearance recurrence.
3. conclusion.
This result of study shows that washout group of the present invention and powder group treatment senile vaginitis total effective rate are 100%, and the cure rate of powder group is higher than the washout group.Have that untoward reaction is light, the safety advantage of higher.And relapse rate is low in 3 months.
Claims (2)
1. pharmaceutical composition for the treatment of senile vaginitis is characterized in that being prepared from by following materials of weight proportions medicine: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Chlorophyti Laxis, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Flos Magnoliae Amoenae, 3 ~ 10 parts of Herba Taxillis, 6 ~ 12 parts of Radix Apioris Fortunei, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Folium Dalbergiae Mimosoidis, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Ramulus Cinnamomi.
2. a kind of pharmaceutical composition for the treatment of senile vaginitis according to claim 1 is characterized in that being prepared from by following materials of weight proportions medicine: 20 parts of Cortex erythrinaes, 10 parts of Herba Chlorophyti Laxis, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310267500.7A CN103285284B (en) | 2013-07-01 | 2013-07-01 | Medical composition for treating senile vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310267500.7A CN103285284B (en) | 2013-07-01 | 2013-07-01 | Medical composition for treating senile vaginitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103285284A true CN103285284A (en) | 2013-09-11 |
| CN103285284B CN103285284B (en) | 2015-04-29 |
Family
ID=49087173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310267500.7A Expired - Fee Related CN103285284B (en) | 2013-07-01 | 2013-07-01 | Medical composition for treating senile vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285284B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316270A (en) * | 2013-07-01 | 2013-09-25 | 丁霄雁 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
| CN103316269A (en) * | 2013-07-01 | 2013-09-25 | 付海霞 | Medicine composition for treating primary enuresis |
| CN103316258A (en) * | 2013-07-01 | 2013-09-25 | *** | Medicine composition for treating infantile vaginitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040941A (en) * | 2007-04-24 | 2007-09-26 | 株洲桦强科技发展有限公司 | Chinese medicine composition for treating skin disease |
| CN101167894A (en) * | 2007-11-09 | 2008-04-30 | 北京中科雍和医药技术有限公司 | Traditional Chinese medicinal washing lotion for treating dermatitis, vulvitis and vaginitis |
| CN101455768A (en) * | 2007-12-12 | 2009-06-17 | 天津市中宝制药有限公司 | Traditional Chinese medicine combination for treating colpitis |
-
2013
- 2013-07-01 CN CN201310267500.7A patent/CN103285284B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040941A (en) * | 2007-04-24 | 2007-09-26 | 株洲桦强科技发展有限公司 | Chinese medicine composition for treating skin disease |
| CN101167894A (en) * | 2007-11-09 | 2008-04-30 | 北京中科雍和医药技术有限公司 | Traditional Chinese medicinal washing lotion for treating dermatitis, vulvitis and vaginitis |
| CN101455768A (en) * | 2007-12-12 | 2009-06-17 | 天津市中宝制药有限公司 | Traditional Chinese medicine combination for treating colpitis |
Non-Patent Citations (1)
| Title |
|---|
| 黄露芬等: "老年性***炎的中医药治疗概况", 《福建中医学院学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316270A (en) * | 2013-07-01 | 2013-09-25 | 丁霄雁 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
| CN103316269A (en) * | 2013-07-01 | 2013-09-25 | 付海霞 | Medicine composition for treating primary enuresis |
| CN103316258A (en) * | 2013-07-01 | 2013-09-25 | *** | Medicine composition for treating infantile vaginitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103285284B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN105233188A (en) | Traditional Chinese medicine composition for treating liver cancer and application of traditional Chinese medicine composition | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN112717113A (en) | Traditional Chinese medicine composition for treating allergic rhinitis and ointment formula and application thereof | |
| CN105343313A (en) | Traditional Chinese medicinal composition for treating senile skin pruritus and preparation method of traditional Chinese medicinal composition | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103285300A (en) | Medicinal composition for treating stress incontinence | |
| CN105125964A (en) | Traditional Chinese medicine preparation for treating pelvic peritonitis and preparation method thereof | |
| CN105169111A (en) | Traditional Chinese medicine composition for treating chronic urticaria and application of traditional Chinese medicine composition | |
| CN103316258B (en) | Medicine composition for treating infantile vaginitis | |
| CN103301354B (en) | Preparation method of powder for treating infantile vaginitis | |
| CN104225311A (en) | Neurasthenia heart and spleen tonifying medicament and preparation method | |
| CN103735778A (en) | Traditional Chinese medicine composition for treating obesity | |
| CN103006957A (en) | Pharmaceutical composition for preventing and treating osteoporosis and preparation method thereof | |
| CN105362617A (en) | Medicine for treating chronic urinary retention and preparation method of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG MEI Free format text: FORMER OWNER: ZHUANG LANLAN Effective date: 20150318 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Mei Inventor after: Shi Ying Inventor after: Liu Shouye Inventor after: Xiao Li Inventor before: Zhuang Lanlan Inventor before: Xiao Li |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHUANG LANLAN XIAO LI TO: WANG MEI SHI YING LIU SHOUYE XIAO LI Free format text: CORRECT: ADDRESS; FROM: 276800 RIZHAO, SHANDONG PROVINCE TO: 255100 ZIBO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150318 Address after: Zichuan District Hospital No. 232 in Shandong province Zibo city Zichuan District 255100 Zicheng road in Shandong Province, Zibo City Applicant after: Wang Mei Address before: 276800 Juxian People's Hospital of Shandong, Rizhao City Province, China Applicant before: Zhuang Lanlan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 Termination date: 20160701 |